Immunotherapeutic Agents in Breast Cancer

In this video, Leisha A. Emens, MD, PhD, of the Sidney Kimmel Cancer Center, reviews some of the challenges to treating breast cancer patients with an immunotherapeutic approach and highlights the latest trials and research on different immunotherapies being tested in this setting, including PD-1 and PD-L1 blockade in patients with triple-negative breast cancer as well as other subtypes.

Emens gave a presentation on this topic at the 2017 American Society for Cancer Research (AACR) Annual Meeting, held April 1–5 in Washington, DC.